Inspire Medical Plunges On Outlook Cut, Weak V System Rollout: Analysts React

Inspire Medical Systems (INSP) shares plummeted over 40% after the company drastically cut its fiscal 2025 EPS guidance to $0.40-$0.50, significantly below the $2.27 consensus, and lowered sales forecasts, despite Q2 sales of $217.09 million beating estimates. The revised outlook is attributed to a slower-than-expected U.S. commercial launch and delayed transition of its new Inspire V neurostimulation system. This significant guidance reduction, coupled with the recent FDA approval of Eli Lilly's Zepbound for obstructive sleep apnea, prompted widespread analyst downgrades and price target reductions.

Analysis

Inspire Medical Systems (INSP) is facing a significant operational and strategic crisis, underscored by a severe reduction in its fiscal 2025 guidance. The company slashed its EPS forecast to $0.40-$0.50 from a prior $2.20-$2.30, a figure drastically below the $2.27 analyst consensus. This was accompanied by a sales guidance cut to $900-$910 million from a previous $940-$955 million. The primary driver for this revision is a slower-than-anticipated U.S. commercial launch of its new Inspire V neurostimulation system. While management has labeled these as "temporary operational headwinds," the magnitude of the cuts suggests a material disruption. The disappointing outlook overshadowed a Q2 that beat top-line estimates with $217.09 million in sales (+11% YoY) and delivered adjusted EPS of 45 cents, more than double the consensus. However, profitability is under pressure, with the company swinging to an operating loss of $3.3 million from a $5.1 million income a year ago, partly due to a $2.1 million inventory charge on its older Inspire IV model. Compounding these internal challenges is a new external threat: the FDA's recent approval of Eli Lilly’s Zepbound for obstructive sleep apnea, which introduces a major pharmaceutical competitor. The market's reaction has been swift and severe, with the stock plunging over 41% and a wave of analyst downgrades and substantial price target reductions from firms including JPMorgan, Keybanc, and Truist, reflecting a dramatic loss of confidence in the company's near-term execution and long-term competitive positioning.

Key Decisions for Investors

• Investors should critically assess whether the operational headwinds impacting the Inspire V launch are truly temporary, as management suggests, or indicative of deeper execution challenges, given the severity of the guidance reduction.
• The recent FDA approval of Eli Lilly's Zepbound introduces a significant pharmaceutical competitor for obstructive sleep apnea, warranting a re-evaluation of Inspire's long-term market share and competitive moat against less invasive treatments.
• Following the stock's sharp repricing and widespread analyst downgrades, it is prudent to monitor for tangible evidence of a successful operational turnaround and stabilization in the Inspire V rollout before considering new long positions.